Meng-Tzu Weng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Meng-Tzu Weng has a total of 130 co-authors. Here are the top co-authors by number of shared publications:
- Shu-Chen Wei
Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
17 shared publications - Chien-Chih Tung
Department of Integrated Diagnostics and Therapeutics and Medical Research, National Taiwan University Hospital, Taipei, Taiwan
7 shared publications - Hsin-Yun Wu
Department of Internal Medicine, National Taiwan University Hospital JinShan Branch, New Taipei, Taiwan
6 shared publications - Kuen-Song Lin
Department of Chemical Engineering and Materials Science/Environmental Technology Research Center, Yuan Ze University, Chung-Li District, Taoyuan City, 32003, Taiwan
5 shared publications - I. -L. Shih
Department of Medical Imaging, National Taiwan University Hospital, Taipei, Taiwan
4 shared publications - Jau-Min Wong
Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan
4 shared publications
Latest Publications
- Open Access
- 19 May 2026
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
Real-world use and perceptions of advanced combined therapies in treating inflammatory bowel disease
Real-world use and perceptions of advanced combined therapies in treating inflammatory bowel disease
- 19 May 2026
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
Open AccessReal-world use and perceptions of advanced combined therapies in treating inflammatory bowel disease
Real-world use and perceptions of advanced combined therapies in treating inflammatory bowel disease
- Open Access
- 24 February 2026
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
Temporal hospitalization trends for inflammatory bowel disease in Taiwan
Temporal hospitalization trends for inflammatory bowel disease in Taiwan
- 24 February 2026
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
Open AccessTemporal hospitalization trends for inflammatory bowel disease in Taiwan
Temporal hospitalization trends for inflammatory bowel disease in Taiwan
- Open Access
- 22 October 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121 (2) , 561-565
Demodicosis Mimics Acneiform Eruptions in Patients With Inflammatory Bowel Disease Receiving Upadacitinib
INTRODUCTION: Acne is a common side effect of inflammatory bowel disease (IBD) treatment. We investigated the role of demodicosis in acne development in patients with IBD. METHODS: From 2019 to 2021, IBD patients with acneiform eruptions were referred for dermatological evaluation. We compared these patients according to the demodicosis status. RESULTS: Of 509 patients with IBD, 30 had acneiform eruptions. Among them, 20 had demodicosis. All were successfully treated without IBD treatment adjustments. Upadacitinib use was the only independent risk factor of demodicosis, occurring in 16 of 18 exposed patients. DISCUSSION: Demodicosis should be considered in patients with IBD having acneiform eruptions, particularly those receiving upadacitinib.
- 22 October 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121 (2) , 561-565
Open AccessDemodicosis Mimics Acneiform Eruptions in Patients With Inflammatory Bowel Disease Receiving Upadacitinib
INTRODUCTION: Acne is a common side effect of inflammatory bowel disease (IBD) treatment. We investigated the role of demodicosis in acne development in patients with IBD. METHODS: From 2019 to 2021, IBD patients with acneiform eruptions were referred for dermatological evaluation. We compared these patients according to the demodicosis status. RESULTS: Of 509 patients with IBD, 30 had acneiform eruptions. Among them, 20 had demodicosis. All were successfully treated without IBD treatment adjustments. Upadacitinib use was the only independent risk factor of demodicosis, occurring in 16 of 18 exposed patients. DISCUSSION: Demodicosis should be considered in patients with IBD having acneiform eruptions, particularly those receiving upadacitinib.
- Open Access
- 4 October 2025
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 125 (2) , 240-241
Response to comment on “Pregnancy and perinatal outcomes of mothers with inflammatory bowel disease in Taiwan: A national database analysis”
- 4 October 2025
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 125 (2) , 240-241
Open AccessResponse to comment on “Pregnancy and perinatal outcomes of mothers with inflammatory bowel disease in Taiwan: A national database analysis”
- 23 June 2025
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 64 (1) , 176-184
Fecal leukocyte esterase levels predict endoscopic severity as an alternative biomarker in inflammatory bowel disease
Objectives: Our previous study revealed a correlation between fecal leukocyte esterase and fecal calprotectin levels. This study assessed the predictive value of fecal leukocyte esterase compared with fecal calprotectin and C-reactive protein of inflammatory bowel disease. Methods: Patients with inflammatory bowel disease who underwent ileocolonoscopy at National Taiwan University Hospital from March 2022 to March 2024 were included. Fecal leukocyte esterase and fecal calprotectin levels from stool samples collected within one month of endoscopy were analyzed. Active ulcerative colitis and Crohn’s disease were defined as Mayo endoscopic score ≥2 or simple endoscopic score for Crohn’s disease ≥7, respectively. Sensitivity, specificity, predictive values, and areas under the receiver operating characteristic curve were calculated using IBM SPSS Statistics 29. Results: Of the 203 patients (100 with ulcerative colitis and 103 with Crohn’s disease), fecal leukocyte esterase levels were significantly correlated with fecal calprotectin levels (r=0.425, p<0.001) and endoscopic severity in ulcerative colitis (r=0.432, p<0.001) and Crohn’s disease (r=0.311, p=0.001). For predicting Mayo endoscopic scores ≥2 in ulcerative colitis using fecal leukocyte esterase, fecal calprotectin, and C-reactive protein, areas under the curve were 0.731, 0.785, and 0.558, respectively. For predicting simple endoscopic scores for Crohn’s disease ≥7, areas under the curve were 0.706, 0.800, and 0.770, respectively. No significant difference was observed between fecal leukocyte esterase and fecal calprotectin. Conclusions: Fecal leukocyte esterase correlates with fecal calprotectin and predicts endoscopic severity in inflammatory bowel disease.
- 23 June 2025
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 64 (1) , 176-184
Fecal leukocyte esterase levels predict endoscopic severity as an alternative biomarker in inflammatory bowel disease
Objectives: Our previous study revealed a correlation between fecal leukocyte esterase and fecal calprotectin levels. This study assessed the predictive value of fecal leukocyte esterase compared with fecal calprotectin and C-reactive protein of inflammatory bowel disease. Methods: Patients with inflammatory bowel disease who underwent ileocolonoscopy at National Taiwan University Hospital from March 2022 to March 2024 were included. Fecal leukocyte esterase and fecal calprotectin levels from stool samples collected within one month of endoscopy were analyzed. Active ulcerative colitis and Crohn’s disease were defined as Mayo endoscopic score ≥2 or simple endoscopic score for Crohn’s disease ≥7, respectively. Sensitivity, specificity, predictive values, and areas under the receiver operating characteristic curve were calculated using IBM SPSS Statistics 29. Results: Of the 203 patients (100 with ulcerative colitis and 103 with Crohn’s disease), fecal leukocyte esterase levels were significantly correlated with fecal calprotectin levels (r=0.425, p<0.001) and endoscopic severity in ulcerative colitis (r=0.432, p<0.001) and Crohn’s disease (r=0.311, p=0.001). For predicting Mayo endoscopic scores ≥2 in ulcerative colitis using fecal leukocyte esterase, fecal calprotectin, and C-reactive protein, areas under the curve were 0.731, 0.785, and 0.558, respectively. For predicting simple endoscopic scores for Crohn’s disease ≥7, areas under the curve were 0.706, 0.800, and 0.770, respectively. No significant difference was observed between fecal leukocyte esterase and fecal calprotectin. Conclusions: Fecal leukocyte esterase correlates with fecal calprotectin and predicts endoscopic severity in inflammatory bowel disease.
- Open Access
- 6 March 2025
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 125 (2) , 200-206
Pregnancy and perinatal outcomes of mothers with inflammatory bowel disease in Taiwan: A national database analysis
- 6 March 2025
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 125 (2) , 200-206
Open AccessPregnancy and perinatal outcomes of mothers with inflammatory bowel disease in Taiwan: A national database analysis
- Open Access
- 20 February 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (2) , e010472
Ethanol inhibits the growth and metastasis of hepatocellular carcinoma by inducing immunogenic cell death
Background Immunogenic cell death (ICD) can elicit an adaptive immune response with significant antitumor effects. Percutaneous ethanol injection therapy has been applied as tumor ablation for small hepatocellular carcinoma (HCC). However, it was not clear whether ethanol can elicit ICD. The aim of this study is to investigate the role of ethanol as an ICD inducer. Methods HCC cell lines were treated with low-concentration ethanol and ICD markers, such as calreticulin, high-mobility group box 1, and ATP were assayed. The mouse vaccination-rechallenge assay was used to further confirm ethanol as an ICD inducer. Western blot and real-time PCR were used to investigate ICD-related endoplasmic reticulum (ER) stress and signaling pathways. The genes with differential expression levels between primary and distant tumors were analyzed by nCounter gene expression. Intratumoral injection of ethanol was done to investigate the abscopal effect. Results The low-concentration ethanol could induce ICD in HCC cell lines through unfolded protein responses initiated by ER stress and multiple cell-death pathways. Intratumoral injections of low-concentration ethanol had significantly direct and abscopal antitumor effects in mouse models of both subcutaneous and orthotopic HCC. nCounter gene expression analysis in primary and distant tumors revealed the activation of various immune-response pathways, notably those mediated by CD8 T cells and the interferon pathway. Vaccinating mice with low-concentration ethanol-treated HCC cells successfully inhibited metastasis in both intravenous and intrasplenic metastasis models. Conclusions Our results suggest that low-concentration ethanol could serve as an inducer of ICD. Low-concentration ethanol could potentially improve therapeutic antitumor immunity by inducing substantial ICD.
- 20 February 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (2) , e010472
Open AccessEthanol inhibits the growth and metastasis of hepatocellular carcinoma by inducing immunogenic cell death
Background Immunogenic cell death (ICD) can elicit an adaptive immune response with significant antitumor effects. Percutaneous ethanol injection therapy has been applied as tumor ablation for small hepatocellular carcinoma (HCC). However, it was not clear whether ethanol can elicit ICD. The aim of this study is to investigate the role of ethanol as an ICD inducer. Methods HCC cell lines were treated with low-concentration ethanol and ICD markers, such as calreticulin, high-mobility group box 1, and ATP were assayed. The mouse vaccination-rechallenge assay was used to further confirm ethanol as an ICD inducer. Western blot and real-time PCR were used to investigate ICD-related endoplasmic reticulum (ER) stress and signaling pathways. The genes with differential expression levels between primary and distant tumors were analyzed by nCounter gene expression. Intratumoral injection of ethanol was done to investigate the abscopal effect. Results The low-concentration ethanol could induce ICD in HCC cell lines through unfolded protein responses initiated by ER stress and multiple cell-death pathways. Intratumoral injections of low-concentration ethanol had significantly direct and abscopal antitumor effects in mouse models of both subcutaneous and orthotopic HCC. nCounter gene expression analysis in primary and distant tumors revealed the activation of various immune-response pathways, notably those mediated by CD8 T cells and the interferon pathway. Vaccinating mice with low-concentration ethanol-treated HCC cells successfully inhibited metastasis in both intravenous and intrasplenic metastasis models. Conclusions Our results suggest that low-concentration ethanol could serve as an inducer of ICD. Low-concentration ethanol could potentially improve therapeutic antitumor immunity by inducing substantial ICD.
- Open Access
- 5 December 2024
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 16 (2) , e00798
Clinical Characteristics, Management, and Outcomes of Colitis-Associated Colorectal Cancer and the Comparison With Sporadic Colorectal Cancer in Taiwan
INTRODUCTION: We explored the clinical characteristics, treatment, and outcomes of colitis-associated colorectal cancer (CAC) and compared with sporadic colorectal cancer in Taiwan. METHODS: In this retrospective study spanning 1987–2022, CACs diagnosed according to endoscopic and pathological reports from 14 tertiary centers were reported to our cohort. Clinical demographics, endoscopic findings, histological results, treatment modalities, and outcomes were analyzed. Sporadic colorectal cancer data were retrieved from the Cancer Registry Annual Report, Ministry of Health and Welfare, Taiwan. RESULTS: We enrolled 65 patients with CAC (median age: 56 years; male: 66.2%). Distal colon was the most common tumor location (41.5%). Of patients with ulcerative colitis, 77.2% had extensive colitis, and 76.5% had Mayo endoscopic subscores of ≥2. Moreover, 50% of lesions were nonpolypoid with indistinct borders in 66.7%. Signet-ring cell subtype consisted of 12.3%. Surveillance colonoscopy adherence was 78.4%, yet 51.3% interval cancers occurred. Disease stage 0–4 distribution was 15%, 20%, 13.3%, 20%, and 31.7%, respectively. Endoscopic resection was feasible for 14%, whereas 67.7% required surgery. During follow-up (median: 21.5 months), we recorded 23.2% recurrence and 34.5% mortality. Lesions with indistinct borders were associated with adverse outcomes (adjusted odds ratio = 11.5 [1.35–98.16]). Colitis-associated rectal cancers, diagnosed later (P < 0.001), had worse outcomes than sporadic rectal cancers. DISCUSSION: This is the largest Asian CAC cohort study, emphasizing the need for stringent disease control, improving detection, and reducing interval cancers. Signet-ring cell subtype was prevalent. Rectal colitis-associated cancers were diagnosed later with poorer outcomes than sporadic rectal cancers.
- 5 December 2024
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 16 (2) , e00798
Open AccessClinical Characteristics, Management, and Outcomes of Colitis-Associated Colorectal Cancer and the Comparison With Sporadic Colorectal Cancer in Taiwan
INTRODUCTION: We explored the clinical characteristics, treatment, and outcomes of colitis-associated colorectal cancer (CAC) and compared with sporadic colorectal cancer in Taiwan. METHODS: In this retrospective study spanning 1987–2022, CACs diagnosed according to endoscopic and pathological reports from 14 tertiary centers were reported to our cohort. Clinical demographics, endoscopic findings, histological results, treatment modalities, and outcomes were analyzed. Sporadic colorectal cancer data were retrieved from the Cancer Registry Annual Report, Ministry of Health and Welfare, Taiwan. RESULTS: We enrolled 65 patients with CAC (median age: 56 years; male: 66.2%). Distal colon was the most common tumor location (41.5%). Of patients with ulcerative colitis, 77.2% had extensive colitis, and 76.5% had Mayo endoscopic subscores of ≥2. Moreover, 50% of lesions were nonpolypoid with indistinct borders in 66.7%. Signet-ring cell subtype consisted of 12.3%. Surveillance colonoscopy adherence was 78.4%, yet 51.3% interval cancers occurred. Disease stage 0–4 distribution was 15%, 20%, 13.3%, 20%, and 31.7%, respectively. Endoscopic resection was feasible for 14%, whereas 67.7% required surgery. During follow-up (median: 21.5 months), we recorded 23.2% recurrence and 34.5% mortality. Lesions with indistinct borders were associated with adverse outcomes (adjusted odds ratio = 11.5 [1.35–98.16]). Colitis-associated rectal cancers, diagnosed later (P < 0.001), had worse outcomes than sporadic rectal cancers. DISCUSSION: This is the largest Asian CAC cohort study, emphasizing the need for stringent disease control, improving detection, and reducing interval cancers. Signet-ring cell subtype was prevalent. Rectal colitis-associated cancers were diagnosed later with poorer outcomes than sporadic rectal cancers.
- 24 August 2024
- Published by Elsevier in Journal of Industrial and Engineering Chemistry
- Vol. 143, 339-353
Synthesis and characterization of oleic acid-stabilized cobalt ferrite @MCM-41/nanocomposites for pH-responsive drug delivery
- 24 August 2024
- Published by Elsevier in Journal of Industrial and Engineering Chemistry
- Vol. 143, 339-353
Synthesis and characterization of oleic acid-stabilized cobalt ferrite @MCM-41/nanocomposites for pH-responsive drug delivery
- Open Access
- 31 July 2024
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
- Vol. 22 (3) , 213-249
Management of ulcerative colitis in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease updated in 2023
Ulcerative colitis (UC) is a chronic inflammation of the gastrointestinal tract and is characterized by alternating periods of inflammation and remission. Although UC incidence is lower in Taiwan than in Western countries, its impact remains considerable, demanding updated guidelines for addressing local healthcare challenges and patient needs. The revised guidelines employ international standards and recent research, emphasizing practical implementation within the Taiwanese healthcare system. Since the inception of the guidelines in 2017, the Taiwan Society of Inflammatory Bowel Disease has acknowledged the need for ongoing revisions to incorporate emerging therapeutic options and evolving disease management practices. This updated guideline aims to align UC management with local contexts, ensuring comprehensive and context-specific recommendations, thereby raising the standard of care for UC patients in Taiwan. By adapting and optimizing international protocols for local relevance, these efforts seek to enhance health outcomes for patients with UC.
- 31 July 2024
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
- Vol. 22 (3) , 213-249
Open AccessManagement of ulcerative colitis in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease updated in 2023
Ulcerative colitis (UC) is a chronic inflammation of the gastrointestinal tract and is characterized by alternating periods of inflammation and remission. Although UC incidence is lower in Taiwan than in Western countries, its impact remains considerable, demanding updated guidelines for addressing local healthcare challenges and patient needs. The revised guidelines employ international standards and recent research, emphasizing practical implementation within the Taiwanese healthcare system. Since the inception of the guidelines in 2017, the Taiwan Society of Inflammatory Bowel Disease has acknowledged the need for ongoing revisions to incorporate emerging therapeutic options and evolving disease management practices. This updated guideline aims to align UC management with local contexts, ensuring comprehensive and context-specific recommendations, thereby raising the standard of care for UC patients in Taiwan. By adapting and optimizing international protocols for local relevance, these efforts seek to enhance health outcomes for patients with UC.